Biosimilar infliximab CPT-13 in inflammatory bowel disease in real clinical setting: pharmacokinetics outcomes, immunogenicity and drug survival.

Conclusion In conclusion, the pharmacokinetic characteristics and incidence of immunogenicity of CPT-13, in real clinical setting, are comparable to those of the infliximab originator. The two products also have similar long-term drug survival and the same safety profile. PMID: 33486961 [PubMed - as supplied by publisher]
Source: Revista Espanola de Enfermedades Digestivas - Category: Gastroenterology Tags: Rev Esp Enferm Dig Source Type: research